Integrated BioPharma Inc (INBP) stock
INBPOTCPharmaceutical PreparationsFiscal year ends June 30
$0.18+0.00 (0.00%)
Close on Oct 19, 2026Market cap $5.59MP/E –Yield –
Earnings
Integrated BioPharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 10, 2027
Q2 FY2027 · estimated, during market hours
Revenue, Q1 FY2027
$9.90M
-22.0% on a year earlier
EPS, Q1 FY2027
-$0.02
$0.00 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Integrated BioPharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2027ended Dec 31, 2026 | Feb 10, 2027Expected | – | – | – | – |
| Q1 FY2027ended Sep 30, 2026 | Nov 13, 2026during market hours | $9.90M | -22.0% | -$0.02 | Release |
| Q4 FY2026ended Jun 30, 2026 | Sep 25, 2026during market hours | $9.80M | -31.0% | -$0.04 | Release |
| Q3 FY2026ended Mar 31, 2026 | May 8, 2026during market hours | $10.10M | -27.3% | -$0.03 | Release |
| Q2 FY2026ended Dec 31, 2025 | Feb 11, 2026during market hours | $11.30M | -10.3% | -$0.03 | Release |
| Q1 FY2026ended Sep 30, 2025 | Nov 10, 2025during market hours | $12.70M | -6.6% | $0.00 | Release |
| Q4 FY2025ended Jun 30, 2025 | Sep 23, 2025during market hours | $14.20M | – | -$0.01 | Release |
| Q3 FY2025ended Mar 31, 2025 | May 14, 2025during market hours | $13.90M | – | $0.02 | Release |
| Q2 FY2025ended Dec 31, 2024 | Feb 13, 2025during market hours | $12.60M | – | $0.00 | Release |
| Q1 FY2025ended Sep 30, 2024 | Nov 14, 2024during market hours | $13.60M | – | $0.01 | Release |
| Q4 FY2024ended Jun 30, 2024 | Sep 23, 2024before the open | – | – | – | Release |
| Q3 FY2024ended Mar 31, 2024 | May 10, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Dec 31, 2023 | Feb 12, 2024during market hours | – | – | – | Release |
| Q1 FY2024ended Sep 30, 2023 | Nov 9, 2023before the open | – | – | – | Release |
| Q4 FY2023ended Jun 30, 2023 | Sep 15, 2023during market hours | – | – | – | Release |
| Q3 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | – | – | – | Release |
| Q2 FY2023ended Dec 31, 2022 | Feb 10, 2023during market hours | – | – | – | Release |
| Q1 FY2023ended Sep 30, 2022 | Nov 14, 2022before the open | – | – | – | Release |
| Q4 FY2022ended Jun 30, 2022 | Sep 14, 2022before the open | – | – | – | Release |
| Q3 FY2022ended Mar 31, 2022 | May 12, 2022during market hours | – | – | – | Release |
| Q2 FY2022ended Dec 31, 2021 | Feb 10, 2022during market hours | – | – | – | Release |
| Q1 FY2022ended Sep 30, 2021 | Nov 10, 2021during market hours | – | – | – | Release |
| Q4 FY2021ended Jun 30, 2021 | Sep 2, 2021during market hours | – | – | – | Filing |
| Q3 FY2021ended Mar 31, 2021 | May 13, 2021during market hours | – | – | – | Filing |
| Q2 FY2021ended Dec 31, 2020 | Feb 12, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Sep 30, 2020 | Nov 12, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Integrated BioPharma has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Integrated BioPharma puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Integrated BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?